Trastuzumab deruxtecan, an anti-HER2 antibody conjugated with a derivative of the camptothecin analog exatecan, is also an FDA-approved regimen for the treatment of metastatic HER2-positive breast cancer 16. The gene discussed is ERBB2; the disease is breast cancer.